Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
Addex Therapeutics Ltd
Geneva, Switzerland
We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-291644) and Form S-8 (No. 333-255124 and No.333-272515) of Addex Therapeutics Ltd (the Company) of our report dated May 15, 2026, relating to the consolidated financial statements appearing in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
BDO AG
/s/ Philipp Kegele | /s/ Nigel Le Masurier |
| |
Zurich, Switzerland, May 15, 2026 | |
Consent of Independent Registered Public Accounting Firm
Neurosterix US Holding LLC
Delaware, USA
We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-291644) and Form S-8 (No. 333-255124 and No.333-272515) of our report dated May 13, 2026, relating to the Neurosterix US Holding LLC consolidated financial statements appearing in Addex Therapeutics Ltd’s Annual Report on Form 20-F for the year ended December 31, 2025.
BDO AG
/s/ Philipp Kegele | /s/ Hanna-Laura Mock |
| |
Zurich, Switzerland, May 15, 2026 | |